youtube_live
Q3 2026 earnings • released • EPS beat +1.25% • Revenue beat +0.61%
See resultschevron_right
ICLR:NASDAQ
ICON PLC
$214.16
arrow_upward
+17.04%(+31.18) 1D
$212.51
arrow_downward
-0.77% (-1.65)bedtimeAfter hours
Closed: Oct 28, 4:00:00 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ICLR...
Open
$199.19
High
$214.94
Low
$195.80
Mkt. cap
16.52B
Avg. vol.
963.69K
Volume
0.00
P/E ratio
238.12
52-wk high
$214.94
52-wk low
$66.58
EPS
$0.90
Beta
1.24
Shares outstanding
77.15M
No. of employees
40K
Open
$199.19
High
$214.94
Low
$195.80
Mkt. cap
16.52B
Avg. vol.
963.69K
Volume
0.00
P/E ratio
238.12
52-wk high
$214.94
52-wk low
$66.58
EPS
$0.90
Beta
1.24
Shares outstanding
77.15M
No. of employees
40K
News stories
From web sources and news partners
Yahoo Finance
·
7 hours ago
Icon PLC (ICLR) (Q3 2026) Earnings Call Highlights: Record $3. ...
kare11.com
·
11 hours ago
Icon PLC: Q3 Earnings Snapshot
TradingView
·
13 hours ago
What Icon (ICLR) Said on Its Q3 Earnings Call
The Globe and Mail
·
15 hours ago
ICON (ICLR) Q3 2026 Earnings Call Transcript
Profile
Icon plc is an Irish-headquartered multinational clinical research organisation. Icon conducts clinical trials on behalf of pharmaceutical and biotechnology companies and provides services related to drug development and guiding clinical trial progress.
As of December 2025 Icon had approximately 40,100 employees in 55 countries. Wikipedia
About ICON PLC
Analyst ratings
Based on 11 analysts giving stock ratings to ICLR in the past 3 months
Buy
Buy
6
Hold
5
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for ICLR in the last 3 months.
Highest
Current $214.16
$226.00 (+5.53%)
Average
$188.38 (-12.04%)
Lowest
$165.00 (-22.95%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Ryan Halsted RBC Capital | Buy | Reiterated | $226.00 | +5.5% | 10/28/2026 |
Elizabeth Anderson CFA Evercore ISI | Buy | Maintained | $180.00 | -16% | 10/28/2026 |
Luke Sergott Barclays | Hold | Maintained | $175.00 | -18.3% | 10/28/2026 |
Kevin Caliendo UBS | Hold | Maintained | $195.00 | -8.9% | 10/20/2026 |
Lu Li Bank of America Securities | Hold | Upgraded | - | - | 10/09/2026 |
Michael Ryskin Bank of America Securities | Hold | Upgraded | - | - | 10/09/2026 |
Patrick B Donnelly Citi | Hold | Maintained | $175.00 | -18.3% | 09/18/2026 |
Albert Hu Citi | Hold | Maintained | $175.00 | -18.3% | 09/18/2026 |
Jailendra Singh Truist Financial | Buy | Reiterated | - | - | 09/17/2026 |
Casey Woodring J.P. Morgan | Hold | Maintained | $165.00 | -23% | 08/04/2026 |
Charles Rhyee TD Cowen | Buy | Reiterated | $197.00 | -8% | 08/03/2026 |
Eric Coldwell Robert W. Baird | Buy | Maintained | $194.00 | -9.4% | 07/31/2026 |
Brendan Digan Citi | Hold | Maintained | $180.00 | -16% | 07/31/2026 |
Jared Haase William Blair | Buy | Reiterated | - | - | 07/29/2026 |
Ann Hynes Mizuho Securities | Buy | Maintained | $190.00 | -11.3% | 06/26/2026 |
Justin Bowers Deutsche Bank | Buy | Maintained | $188.00 | -12.2% | 06/25/2026 |
David Windley Jefferies | Buy | Reiterated | $193.00 | -9.9% | 06/25/2026 |
Sean Dodge BMO Capital | Buy | Maintained | $187.00 | -12.7% | 06/25/2026 |
Max Smock William Blair | Buy | Reiterated | - | - | 06/02/2026 |
Michael Cherny Leerink Partners | Hold | Maintained | $145.00 | -32.3% | 05/28/2026 |
Jamie Clark Rothschild & Co Redburn | Hold | Downgraded | $100.00 | -53.3% | 02/17/2026 |
Last report
Oct 28, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$2.66 / $2.63
+1.25%beat
arrow_upward
Revenue / Est. (USD)
2.02B / 2.01B
+0.61%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 2.04B | 2.19B | 2.03B | 2.06B |
Cost of goods sold | 1.49B | 1.69B | 1.55B | 1.58B |
Cost of revenue | 1.49B | 1.69B | 1.55B | 1.58B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 198.75M | -605.04M | 202.30M | 195.92M |
Operating expense | 297.24M | 850.77M | 292.63M | 286.68M |
Total operating expenses | 1.78B | 2.54B | 1.85B | 1.87B |
Operating income | 258.90M | -355.01M | 187.00M | 194.21M |
Other non operating income | - | -9.38M | - | - |
EBT including unusual items | 38.10M | -142.45M | 127.56M | 92.20M |
EBT excluding unusual items | 210.42M | -409.19M | 140.82M | 148.58M |
Income tax expense | 35.75M | -17.01M | 22.81M | 19.62M |
Effective tax rate | 93.82% | 11.94% | 17.88% | 21.27% |
Other operating expenses | - | 1.70B | - | - |
Net income | 2.36M | -125.44M | 104.75M | 72.58M |
Net profit margin | 0.12% | -5.73% | 5.15% | 3.52% |
Earnings per share | 3.31 | 2.52 | 2.50 | 2.56 |
Interest and investment income | 1.76M | 1.49M | 1.82M | 3.16M |
Interest expense | -50.24M | -46.29M | -48.00M | -48.79M |
Net interest expenses | -48.48M | -44.80M | -46.18M | -45.63M |
Depreciation and amortization charges | 98.50M | -292.17M | 90.33M | 90.77M |
EBITDA | 357.40M | -264.19M | 277.33M | 284.98M |
Gain or loss from assets sale | - | - | - | 32.95M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events